Research and Development Expenses Breakdown: Novartis AG vs BioMarin Pharmaceutical Inc.

R&D Spending: Novartis vs BioMarin - A Decade of Innovation

__timestamp	BioMarin Pharmaceutical Inc.	Novartis AG
Wednesday, January 1, 2014	461543000	9086000000
Thursday, January 1, 2015	634806000	8935000000
Friday, January 1, 2016	661905000	9039000000
Sunday, January 1, 2017	610753000	8972000000
Monday, January 1, 2018	696328000	9074000000
Tuesday, January 1, 2019	715007000	9402000000
Wednesday, January 1, 2020	628116000	8980000000
Friday, January 1, 2021	628793000	9540000000
Saturday, January 1, 2022	649606000	9996000000
Sunday, January 1, 2023	746773000	11371000000
Monday, January 1, 2024	747184000	10022000000

Unlocking the unknown

A Decade of Innovation: R&D Spending in Pharmaceuticals

In the ever-evolving world of pharmaceuticals, research and development (R&D) is the lifeblood of innovation. Over the past decade, Novartis AG and BioMarin Pharmaceutical Inc. have demonstrated contrasting yet significant commitments to R&D. Novartis, a global healthcare giant, consistently allocated around 9% of its revenue to R&D, peaking in 2023 with a 13% increase from 2014. Meanwhile, BioMarin, a leader in rare disease therapies, showed a steady rise in R&D investment, culminating in a 62% increase over the same period. This trend underscores the industry's relentless pursuit of groundbreaking treatments and therapies. As we look to the future, these investments are poised to drive the next wave of medical breakthroughs, offering hope to millions worldwide.

Published by

U.S. Securities and Exchange Commission

Source link

sec.gov

Date published

17 Jan 2025